Cancer drug combo tested for rare skin cancer – but study never started
NCT ID NCT05846724
First seen Jan 24, 2026 · Last updated May 01, 2026 · Updated 18 times
Summary
This study aimed to test a combination of two drugs, pembrolizumab and lenvatinib, in people with classic Kaposi sarcoma that had not responded to prior chemotherapy. The goal was to see if the combination could shrink tumors better than standard chemotherapy. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.